In adult patients requiring an ACE inhibitor for hypertension, heart failure, or diabetic kidney protection, which is preferred, enalapril or lisinopril?

Enalapril vs Lisinopril: Clinical Selection

Both enalapril and lisinopril are equally effective ACE inhibitors for mortality and morbidity reduction in hypertension, heart failure, and diabetic kidney disease, but lisinopril is preferred due to its superior 24-hour blood pressure control with once-daily dosing and simpler pharmacokinetics. 1, 2

Efficacy Comparison

Cardiovascular Outcomes

• No significant difference in mortality or major cardiovascular outcomes between enalapril and lisinopril in heart failure or post-MI patients 1, 3, 4
• Both agents reduce hospital admissions, improve NYHA class, and increase survival in heart failure when titrated to target doses 1
• Target dosing: enalapril 10-20 mg twice daily vs lisinopril 20-40 mg once daily 1, 3

Blood Pressure Control

• Lisinopril provides consistently better 24-hour blood pressure control than enalapril with once-daily dosing 2, 5
• Lisinopril achieves higher trough-to-peak ratios (>50-60%) compared to enalapril, meeting FDA criteria for sustained antihypertensive effect 5
• Both agents are less effective as monotherapy in Black patients; combination with thiazide diuretics or calcium channel blockers is recommended 6, 7, 8

Renal Protection

• Both agents are equally effective for diabetic nephropathy and chronic kidney disease 9, 10, 11
• Lisinopril at 40 mg once daily provides additional reductions in albuminuria compared to 20 mg, with acceptable safety 12
• ACE inhibitors (at maximal tolerated doses) should be first-line therapy when albuminuria is present 9

Pharmacokinetic Advantages of Lisinopril

Dosing Convenience

• Lisinopril requires once-daily dosing vs twice-daily for enalapril, improving adherence 1, 3, 2
• Lisinopril is not a prodrug and does not require hepatic conversion, unlike enalapril 2, 13
• Peak effect occurs at 6-7 hours with sustained action over 24 hours 8

Renal Dosing

• Both agents require dose adjustment when creatinine clearance <30 mL/min 1, 13
• Lisinopril is eliminated unchanged by the kidneys and may be preferred in hepatic disease 2, 13
• Starting doses: enalapril 2.5 mg twice daily; lisinopril 2.5-5 mg once daily 1, 3

Practical Implementation

Initiation and Titration

• Start low and titrate every 2 weeks to target dose 1
• Monitor blood pressure, serum creatinine, and potassium at baseline and 1-2 weeks after initiation or dose changes 1, 14
• Accept creatinine increases up to 50% above baseline or to 3 mg/dL (266 μmol/L), whichever is greater 1

Common Pitfalls to Avoid

• Do not discontinue for asymptomatic hypotension—only symptomatic hypotension requires intervention 1
• ACE inhibitor-induced cough rarely requires discontinuation; exclude pulmonary congestion first 3, 1
• If cough is persistent and troublesome after rechallenge, switch to an ARB with a minimum 6-week washout if prior angioedema 3, 14
• Never combine ACE inhibitors with ARBs—this increases adverse events without improving outcomes 6, 7, 14

Special Populations

• Heart failure: Both agents reduce mortality; lisinopril's once-daily dosing may improve adherence 1, 3, 4
• Post-MI with LV dysfunction: Both are effective; lisinopril studied in GISSI-3 with similar outcomes in elderly and younger patients 10, 15
• Diabetic nephropathy: Both equally effective; lisinopril 40 mg may offer additional albuminuria reduction 9, 10, 12
• Black patients: Combine with calcium channel blocker or thiazide diuretic for optimal blood pressure control 6, 7, 8

Safety Profile

Adverse Effects

• Both agents have similar adverse effect profiles typical of the ACE inhibitor class 3, 10, 4
• Angioedema occurs in <1% of patients, is more frequent in Black individuals, and contraindicates all future ACE inhibitor use 3, 14
• Hyperkalemia risk increases with CKD, diabetes, or concomitant potassium-sparing agents 1, 9, 14
• Enalapril associated with higher incidence of cough and gastrointestinal discomfort in some comparative analyses 4

Monitoring Requirements

• Check serum creatinine and potassium at baseline, 1-2 weeks after initiation, and with each dose increase 1, 14
• Potassium >5.0 mmol/L or creatinine >2.5 mg/dL (>221 μmol/L) requires specialist consultation before initiation 1
• Temporary discontinuation required before iodinated contrast procedures in patients with eGFR 30-60 mL/min/1.73 m² 9